-
Published 7/21/2016
Gari HH, DeGala GD, Ray R, Lucia MS, Lambert JR. PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion. Cancer Lett. 2016 Oct 01; 380(2):505-12. PMID: 27452906.
-
Published 3/29/2016
Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR. Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. Oncotarget. 2016 Mar 29; 7(13):15757-71. PMID: 26909599.
-
Published 10/1/2014
Gari HH, Ray R, Lucia S, Porter CC, Gearheart CM, Fosmire S, Degala GD, Fan Z, Ru Y, Thor AD, Lambert JR. Cancer Research. Abstract 4604: PTP4A3 is oncogenic and modulates triple negative breast cancer growth. 2014; 74(19):4604.
-
Published 9/13/2013
Datta-Mitra A, Mitra A, Ray R, Raychaudhuri SP, Kundu-Raychaudhuri S. 1,25-Dihydroxyvitamin D3-3-bromoacetate, a novel vitamin D analog induces immunosuppression through PI3K/Akt/mTOR signaling cascade. Int Immunopharmacol. 2013 Nov; 17(3):744-51. PMID: 24036370.
-
Published 1/11/2013
Datta Mitra A, Raychaudhuri SP, Abria CJ, Mitra A, Wright R, Ray R, Kundu-Raychaudhuri S. 1a,25-Dihydroxyvitamin-D3-3-bromoacetate regulates AKT/mTOR signaling cascades: a therapeutic agent for psoriasis. J Invest Dermatol. 2013 Jun; 133(6):1556-64. PMID: 23314787.